Boehringer, Lilly (LLY) Receive European Marketing Approval for Jentadueto
Tweet Send to a FriendGet Alerts LLY Hot Sheet
Price: $55.90 -0.07%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 3.5%
Revenue Growth %: 0.0%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 3.5%
Revenue Growth %: 0.0%
Trade LLY Now!
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the receipt of Marketing Authorization from the European Commission for Jentadueto (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta tablets, marketed under the trade name Trajenta® in Europe) and metformin in a single tablet taken twice daily.
The European Commission has approved JENTADUETO for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on their maximally tolerated dose of metformin alone, metformin and a sulfonylurea, or those already being treated with the combination of linagliptin and metformin. It may be used with a sulfonylurea, as well. JENTADUETO provides a new, single-tablet treatment option, taken twice daily, for adults with type 2 diabetes who need to improve control of their blood glucose.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The European Commission has approved JENTADUETO for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on their maximally tolerated dose of metformin alone, metformin and a sulfonylurea, or those already being treated with the combination of linagliptin and metformin. It may be used with a sulfonylurea, as well. JENTADUETO provides a new, single-tablet treatment option, taken twice daily, for adults with type 2 diabetes who need to improve control of their blood glucose.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Santarus (SNTS) to Present Additional Data on UCERIS
- Mylan (MYL) Unit Launches Generic Zomig Tabs
- Sanofi (SNY) Reports JAKARTA Met Primary Endpoint in Both Groups
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
